

SUNDAY, APRIL 23 - 2006

**TRAINING COURSE – TC1 / TC2
(Parallel session)**

EMERGING ISSUES ON HPV INFECTION: FROM SCIENCE TO PRACTICE

Program Director: J. MONSONEGO (France)

08:15 - 09:30

ROOM BORDEAUX

TC1-1 – HIGH RISK AND LOW RISK HPV INFECTIONS: THE BASIC DIFFERENCES

Chair: X. BOSCH (Spain)

- | | |
|--|----------------------------------|
| 1 – Molecular Biology: Basic Differences | M.Von KNEBEL-DOEBERITZ (Germany) |
| 2 – Distinct Epidemiology and Natural History | E. FRANCO (Canada) |
| 3 – Different Immune Recognition | M. STANLEY (UK) |
| 4 – Different Managing and Patient Counselling | M. SAVARD (USA) |
| 5 – Discussion | |

09:30-10:45

ROOM BORDEAUX

TC1-2 – METHODS FOR HPV DETECTION

Chair: C. MEIJER (Netherlands)

- | | |
|-------------------------------|---------------------------|
| 1 – Hybrid capture technology | A. LORINCZ (USA) |
| 2 – PCR methods | S. GARLAND (Australia) |
| 3 – Molecular markers | P. SNIJDERS (Netherlands) |
| 4- RNA technology | F. KARLSEN (Norway) |
| 5 – Discussion | |

10:45-11:15 – Coffee Break

11:15-12:30

ROOM BORDEAUX

TC1-3 – HPV TESTING AND PATIENT MANAGEMENT

Chair: T. COX (USA)

- | | |
|--|-----------------------|
| 1 – Screening | J. CUZICK (UK) |
| 2 – Management ASC-US / L.SIL | T. COX (USA) |
| 3 – Management H-SIL/AGC | T. WRIGHT (USA)/ |
| 4 – Interpretation of HPV test results | J. MONSONEGO (France) |
| 5 – Discussion | |

13:30-14:45

ROOM BORDEAUX

TC1-4 - MORPHOLOGICAL DIAGNOSIS AND TREATMENT DECISIONS

Chair: A. FERENCZY (Canada)

1 – Cytology; conventional and new techniques

E. MC GOOGAN (UK)

2 – Histology

K. SYRJÄNEN (Finland)

3 – Colposcopy

A. SINGER (UK)

4 – Basic treatment options (CIN, WARTS)

A. FERENCZY (Canada)

5 – Discussion

14:45-15:00 : Coffee Break

15:00-17:15

ROOM BORDEAUX

TC2 – PREVENTION BY VACCINES: CURRENT STATUS, IMPACT AND PROSPECTS

Chair: D. HARPER (USA)

1 – Rationale for HPV vaccines

X. BOSCH (Spain)

2 – Immunogenicity and safety

L. VILLA (Brazil)

3 – HPV vaccine efficacy

J. SCHILLER (USA)

4 – Assessment and follow-up of HPV vaccine efficacy

E. BARR (USA)

5 – Cost-effectiveness of vaccination programmes

E. MYERS (USA)

6 – Unresolved issues and future expectations

R. BARNABAS (UK)

7 – Public health issues related to HPV vaccines

D. JENKINS (Belgium)

8 – How to implement HPV vaccines in practice

D. HARPER (USA)

9 - Discussion

SUNDAY, APRIL 23 - 2006

**TRAINING COURSE - TC3
(Parallel Session)**

COLPOSCOPY

Program Director: A. SINGER (UK)

**Chairs: J.C. BOULANGER (France)
H. JONES III Jr (USA)**

08:15 – 09:45

ROOM 342A

TC3-1 – DIAGNOSIS OF CIN

- | | |
|--|-----------------------|
| 1 – Basic principles | H. JONES III Jr (USA) |
| 2 – Colposcopy of the normal cervix | A. SINGER (UK) |
| 3 – Colposcopy of the CIN and HPV infection:
new nomenclature | P. WALKER (UK) |
| 4 – Grading colposcopic features | S. DEXEUS (Spain) |
| 5 – Colposcopy of glandular lesions | W.C. WRIGHT (Canada) |

09:45-10:45

ROOM 342A

TC3-2 – TREATMENT OF CIN

- | | |
|--|--------------------------|
| 1 – How to treat? | W. PRENDIVILLE (Ireland) |
| 2 – Results in HPV screening and treatment of CIN
in developing Countries | S. TATTI (Argentina) |
| 3 – Complications – Follow up | J.L. LEROY (France) |

10:45-11:15 – Coffee Break

11:15-12:30

ROOM 342 A

TC3-3 – INTERACTIVE COURSE: Case studies

CASE STUDIES:

- A. SINGER (UK)
- W.C. WRIGHT (Canada)
- P. WALKER (UK)
- H. JONES III.Jr (USA)
- J.L. LEROY (France)
- W. PRENDIVILLE (Ireland)

SUNDAY, APRIL 23 –2006

**TRAINING COURSE – TC4
(Parallel Session)**

VULVAR DISEASES

Program Director: R.W. JONES (New Zealand)

**Chairs: M. ROY (Canada)
J. BORNSTEIN (Israel)**

14:00- 15:15

ROOM 342A

TC4 – PART I

- | | |
|---|----------------------------------|
| 1 – Principles of managing vulvar disorders | R.W. JONES (New Zealand) |
| 2 – The vulva: from normal to disease | M. ROY (Canada) |
| 3 – Vulvodynia, state of the art | J. BORNSTEIN (Israël) |
| 4 – Vulvar pruritus: what to do when nothing seems to help? | C. de BELILOVSKY-DOMMEL (France) |
| 5 – Discussion | |

15:15-15:45 – Coffee Break

15:45-17:15

ROOM 342 A

TC4 –2 –PART II

- | | |
|---|-----------------------|
| 5 – Genital herpes: new guidelines | J. BORNSTEIN (Israël) |
| 6 – Lichen sclerosus and vulvar hyperplasia | M. SIDERI (Italy) |
| 7 – Diagnosis and treatment of VIN | B. PANIEL (France) |
| 8 – How to manage genital warts? | A. FERENCZY (Canada) |
| 9 – Psychosomatic issues of vulvar diseases | M. STEBEN (Canada) |
| 10 – Discussion | |

SUNDAY, APRIL 23 –2006

**TRAINING COURSE – TC5
(Parallel Session)**

CYTOPATHOLOGY

**Program Directors: E.MC GOOGAN (UK)
R. ASHFAQ (USA)**

08:00-10:30

ROOM 342 B

TC5-1 – PART I

- | | |
|---|-----------------------|
| 1 – Historical aspects | E. MC GOOGAN (UK) |
| 2 – Basic issues and terminology | A. FERENCZY (Canada) |
| 3 – Liquid-based cytology and image-based screening | R. ASHFAQ (USA) |
| 4 – Computer-assisted automation | J. LINDER (USA) |
| 5 – Proliferation and differentiation markers | K. SYRJÄNEN (Finland) |
| 6 – Molecular techniques in cytodiagnosis | J. DOORBAR (UK) |
| 7 –HPV DNA integration as a prospective marker for high grade disease | F. GARCIA (USA) |
| 8 - Discussion | |

10:30-11:00 – COFFEE BREAK

11:00-12:30

ROOM 342 B

TC5-2 - PART II

Interactive Case Studies: Contribution by the experts

- | |
|-----------------------|
| E. MC GOOGAN (UK) |
| R. ASHFAQ (USA) |
| J. DOORBAR (UK) |
| K. SYRJÄNEN (Finland) |
| J. LINDER (USA) |
| A. FERENCZY (Canada) |

SUNDAY, APRIL 23 –2006

**TRAINING COURSE – TC6
(Parallel Session)**

MOLECULAR MARKERS OF CIN AND CERVICAL CARCINOMA

14:00 – 15:15

ROOM 342 B

TC6 – PART 1

Program Director: Von KNEBEL-DOEBERITZ (Germany)

Chair: K. SYRJÄNEN (Finland)

- | | |
|---|--------------------------------------|
| 1 –Molecular mechanisms in CIN and cancer | M. Von KNEBEL-DOEBERITZ
(Germany) |
| 2 – Chromosomal signatures | P. SNIJDERS (Netherlands) |
| 3 – HPV DNA testing for prediction of CIN – HC2 and
Amplicor HPV test | J. DILLNER (Sweden) |
| 4 – Clinical value of genotyping: the role of specific types as a
marker for progression | P. CASTLE (USA) |
| 5 – Discussion | |

15:15-15:30 – COFFEE BREAK

15:30-17:15

ROOM 342 B

TC6 – PART 2

Program Director: Von KNEBEL DOEBERITZ (Germany)

**Chairs: K. SYRJÄNEN (Finland)
P.CASTLE (USA)**

- | | |
|--|---------------------|
| 5 – Viral load | A. LORINCZ (USA) |
| 6 – Microarray technology | J. DOORBAR (UK) |
| 7 – mRNA technology | M. DÜRST (Germany) |
| 8 – p16 ^{INK4a} over expression in cervical dysplasia
and future possible clinical utility | D. DABBS (USA) |
| 9 – ProExC technology – Detection of aberrant S-Phase induction
in cervical neoplasia | D. MALINOWSKI (USA) |
| 10 - Discussion | |

SUNDAY, APRIL 23 –2006

**TRAINING COURSE – TC7
(Parallel Session)**

OFFICE GYNECOLOGICAL IMAGING

Program Director: J.L. MERGUI (France)

08:30-10:00

ROOM 341

TC7-1 – OFFICE GYNECOLOGICAL PROCEDURES

**Chairs: Walter PRENDIVILLE (Ireland)
Luis PARDAL (Portugal)**

- | | |
|--|--------------------------|
| 1 – Cervical treatment and type of TZ | W. PRENDIVILLE (Ireland) |
| 2 – Hysteroscopic tubal sterilisation | J.L. MERGUI (France) |
| 3 – Thermal ablation for menorrhagias | L. BOUBLI (France) |
| 4 – Management of vulvar and anal HPV infections | L. PARDAL (Portugal) |
| 5 – Discussion | |

10:00-10:30 – COFFEE BREAK

10:30-12:30

TC7-2 – ADVANCE GYNECOLOGICAL PROCEDURES

**Chairs: J.L. MERGUI (France)
M. ROY (Canada)**

- | | |
|--|-----------------------|
| 1 – Sentinel lymph node in pelvic gynaecological cancers | E. BARRANGER (France) |
| 2 – Laparoscopic management of cervical cancer | E. DARAI (France) |
| 3 – Conservative management of cervical cancer | M. ROY (Canada) |
| 4 – Contribution of the Pipelle Mark II in the screening-diagnosis of endometrial cancer | E. CORNIER (France) |
| 5 – Discussion | |
| 6 – Call for a research study on endometrial cancer screening in menopausal women | E. CORNIER (France) |
| 7 – Discussion | |

SUNDAY, APRIL 23 – 2006

**SEMINAR – SEM1 / SEM2
(Parallel Session)**

CERVICAL CANCER SCREENING

13:30 – 14:45

ROOM 341

**SEM 1-1 - EXPERIENCE OF HPV TESTING IN CERVICAL CANCER SCREENING
EUROPE/NORTH AMERICA**

**Program Directors: J. PATNICK (UK)
E. FRANCO (Canada)**

A – EUROPE

- France
- Italy
- Germany
- UK
- Sweden
- The Netherlands

C. CLAVEL (France)
G. RONCO (Italy)
K.U. PETRY (Germany)
P. WALKER (UK)
J. DILLNER (Sweden)
M.Van BALLEGOIJEN (Netherlands)

B – THE NORTH AMERICAN EXPERIENCE

- USA
- Canada

W. KINNEY (USA)
E. FRANCO (Canada)

14:45-15:45

ROOM 341

SEM 1-2 - PUBLIC HEALTH ISSUES

**Program Directors: J. PATNICK (UK)
E. FRANCO (Canada)**

1- European guidelines for cervical cancer screening
2– Public awareness
3– Screening Programme
4- Challenging the future

M. ARBYN (Belgium)
P. DAVIES (UK)
M. HAKAMA (Finland)
J. PATNICK (UK)

15:45-16:00 – COFFEE BREAK

16:00-17:30

ROOM 341

SEM 2: DEVELOPING COUNTRIES

Chairs: **N. MUNOZ (France)
R. SANKARANARAYANAN (France)**

1 – Cytology and HPV testing (LAMS STUDY)
2 – VIA & VILI
3 – Real time screening methods
4 – Screening techniques relevant to developing countries
5 – Discussion

K. SYRJÄNEN (Finland)
R. SANKARANARAYANAN (France)
A. SINGER (UK)
A. LORINCZ (USA)

OC - OPENING CEREMONY

19:00 – 20:00

ROOM BORDEAUX

**Chairs : A. SINGER (UK)
J. SCHILLER (USA)**

1 - WELCOME:

J. MONSONEGO (France)
A.SINGER (UK)

2 - KEYNOTE ADDRESS:

The changing landscape of cervical cancer prevention

T. WRIGHT (USA)

3 - EUROGIN RECOGNITION AND DISTINGUISHED SERVICE AWARDS:

Chair : J. MONSONEGO (France)

- Jan Walboomers Award

- Distinguished Services Award:

Tom COX (USA)
J. CUZICK (UK)
P. CASTLE (USA)
C. CLAVEL (France)
M. von KNEBEL DOEBERITZ (Germany)
T. WRIGHT (USA)
D. HARPER (USA)
X. BOSCH (Spain)
E. FRANCO (Canada)
C. MEIJER (the Netherlands)

20:00 - WELCOME COCKTAIL

MONDAY, APRIL 24 - 2006

PLENARY SESSIONS

PS1 - INNOVATIONS IN CERVICAL CANCER PREVENTION: SCIENCE, PRACTICE AND ACTIONS

08:00 – 08:45

ROOM BORDEAUX

PS1-1 - HPV DNA TESTING IN CERVICAL CANCER SCREENING: FROM EVIDENCE TO POLICIES

Chair : T. COX (USA)

J. CUZICK (UK)

1 – The US experience

T. WRIGHT (USA)

2 – The European perspective

J. DILLNER (Sweden)

3 – Application in developing countries

J. SELLORS (USA)

4 – Consensus

T. COX (USA)

J. CUZICK (UK)

Working group:

T. WRIGHT

T. IFTNER

J. SHERRIS

H. KITCHENER

C. MEIJER

G. RONCO

J. DILLNER

W. KINNEY

K.U. PETRY

E. MYERS

M. VAN BALLEGOIJEN

M. ARBYN

A. LORINCZ

C. CLAVEL

08.45-09:30

ROOM BORDEAUX

PS1-2 -CURRENT KNOWLEDGE AND CLINICAL USE OF HPV GENOTYPING

Chairs: P. CASTLE (USA)

C. MEIJER (Netherlands)

1 –Research update

T. WRIGHT (USA)

2 – Meta-analysis

E. MYERS (USA)

3 – Consensus

P. CASTLE (USA)

C. MEIJER (Netherlands)

Working group:

T. WRIGHT

S. GOLDIE

S. KULASINGAM

G. CLIFFORD

N. MUNOZ

S. FRANCESCHI

E. FRANCO

S. KJAER

J. LINDER

R.APPLE

MONDAY, APRIL 24 - 2006

PLENARY SESSIONS

09:30 – 10:15

ROOM BORDEAUX

PS1-3 - MOLECULAR MARKERS: HOW TO APPLY IN PRACTICE?

Chairs: M.Von KNEBEL DOEBERITZ (Germany)
K. SYRJÄNEN (Finland)

- | | |
|--|--|
| 1 - The role of viral expression in mRNA | J. DOORBAR (UK) |
| 2 - The value of P16 | M. von KNEBEL-DOEBERITZ(Germany) |
| 3 - Assessing the risk of disease and cost-effectiveness | E. MYERS (USA) |
| 4 - Future prospects | K. SYRJÄNEN (Finland)
M. von KNEBEL-DOEBERITZ (Germany) |

Working group:

*P. SNIJDERS
J. DOORBAR
P. CASTLE
J. DILLNER
M. DURST
M. STOLER*

*P. VASSILAKOS
V. SCHNEIDER
L. VILLA
K. CUSHIERI
E.MYERS
R.RIDDER
D. MALINOWSKI*

10:15-10:45-COFFEE BREAK

10:45-11:30

ROOM BORDEAUX

**PS1-4 - PREVENTION STRATEGIES OF CERVICAL CANCER IN
THE HPV VACCINE ERA: CHALLENGES FOR SUCCESS**

Chairs: D. HARPER (US)
X. BOSCH (Spain)

- | | |
|---|------------------------------------|
| 1 – Research update | J. SCHILLER (USA) |
| 2 –Access and other public health issues | F. CUTTS (Switzerland) |
| 3 – New prevention strategies: screening versus vaccine | H. LAWSON (USA) |
| 4 – Recommendations for future development | D. HARPER (UK)
X. BOSCH (Spain) |

Working group:

*J. SCHILLER
H. LAWSON
F. CUTTS
S. KULASINGAM
G. GARNETT*

*M. KANE
E.FRANCO
N. MUNOZ
P. VAN DAMME
J. SCHMITT*

MONDAY, APRIL 24 - 2006

PLENARY SESSIONS

14:00-16:00

**PS2 - STRATEGIC PARTNERSHIPS: THE ROLE OF INSTITUTIONS,
SCIENTIFIC SOCIETIES AND PATIENT GROUPS**

Chairs: P. BOYLE (France)
J. SHERRIS (USA)

1 – Lecture: the challenge of partnerships in cervical cancer control

P. BOYLE (UK)

Expert panel: presentations by the participating groups:

14:20-15:00

ROOM BORDEAUX

PS2-1 - INSTITUTIONS

- European Commission

K. FREESE (Luxemburg)

- INCa (Institut National du Cancer)

C. MAHE (France)

- IARC (Int. Agency for Research on Cancer) /WHO

R. SANKARANARAYANAN
(France)

- CDC (Centre for Disease Control)

H. LAWSON (USA)

- NCI (National Cancer Institute)

P. CASTLE (USA)

15:00-15:30

ROOM BORDEAUX

PS2-2 - SCIENTIFIC SOCIETIES

- ACS (American Cancer Society)

D. SASLOW (USA)

- IFCPC (International Federation of Colposcopy and Cervical
Pathology)

H. JONES (USA)

- ASCCP (American Society of Colposcopy and Cervical Pathology)

T. COX (USA)

- EFC (European Federation of Colposcopy)

E. DIAKOMANOLIS (Greece)

- ISSVD (International Society for the Study of Vulvo-Vaginal Disease)

R.W. JONES (New Zealand)

15:20-16:00

ROOM BORDEAUX

PS2-3 - PATIENT GROUPS

- E.I.W.H. (European Institute of Women's Health)

P. MAGUIRE (Ireland)

- A.C.C.P. (Alliance for Cervical Cancer Prevention)

J. SHERRIS (USA)

- Women in Government

S. CROSBY (USA)

- Balm in Gilead

P. SEELE (USA)

16:00-16:30: Coffee Break

MONDAY, APRIL 24 - 2006

PLENARY SESSIONS

16:30-17:30

ROOM BORDEAUX

**PS3 - THE ESSENTIAL LIBRARY ON HPV AND CERVICAL CANCER:
RESEARCH, PREVENTION, EDUCATION, HEALTH PROMOTION, AND
CLINICAL GUIDELINES AND RECOMMENDATIONS**

Chairs:

	E. FRANCO (Canada) P. BOSZE (Hungary)
1) Basic and fundamental research (10')	K. SYRJÄNEN (Finland) S. TATTI (Argentina)
2) Clinical research (10')	T. WRIGHT (USA) P. BOSZE (Hungary)
3) Population health research (10')	X. BOSCH (Spain) E. FRANCO (Canada)
4) Health promotion research (10')	J. PALEFSKY (USA) A. FERENCZY (Canada)
5) Training and educational materials (10')	J. SHERRIS (USA) P. DAVIES (USA)
6) CME journals and textbooks (10')	P. HILLEMANN (Germany) A. LALONDE (Canada)
7) Guidelines and recommendations (10')	M. ARBYN (Belgium) T. COX (USA)